Kronos Bio Inc
(NAS:KRON)
$
0.94
0.02 (2.17%)
Market Cap: 56.72 Mil
Enterprise Value: -43.55 Mil
PE Ratio: 0
PB Ratio: 0.51
GF Score: 32/100 Kronos Bio Inc at Goldman Sachs Healthcare Conference Transcript
Jun 15, 2023 / 05:40PM GMT
Release Date Price:
$1.7
(+4.94%)
Salveen Richter
Goldman Sachs - Analyst
Great. Good morning, everyone. Thanks for joining us. Really pleased to have with us the Kronos team. We have Norbert Bischofberger, President and CEO; Yasir Al-Wakeel, CFO and Head of Corporate Development; and Jorge DiMartino --
Charles Lin
Kronos Bio, Inc. - SVP, Biology
I'm Charles.
Salveen Richter
Goldman Sachs - Analyst
Actually, Charles -- sorry. Charles, SVP of Biology.
Charles Lin
Kronos Bio, Inc. - SVP, Biology
Jorge couldn't make it.
Questions & Answers
Salveen Richter;Norbert Bischofberger
Goldman Sachs - Analyst;Kronos Bio, Inc. - President, CEO,
Yes. So maybe to start here, maybe 0742, your CDK inhibitor. It's the first molecule to emerge from your platform. Can you start by walking through the key takeaways for the first -- from the first data release that you provided as well as the rationale for your Phase 2 dose selection?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot